In CMS patients due to COLQ, DOK7 and LAMB2 mutations sympathomimetics like ephedrine and salbutamol have been shown to have a clear beneficial effect without major side effects [21,22]. The gene discussed is COLQ; the disease is congenital myasthenic syndrome.